Dehydroepiandrosterone.

Pregnenolone is converted by CYP17A1 through 17-hydroxypregnenolone to DHEA, so it sits one enzymatic step upstream. Supplying both loads the same pathway at two points.

3-beta-hydroxysteroid dehydrogenase converts DHEA to androstenedione, the branch point toward both testosterone and oestrone. The two are consecutive members of one pathway.

17-beta-hydroxysteroid dehydrogenase reduces DHEA to androstenediol, which retains weak androgen receptor and oestrogen receptor activity of its own. It is one reduction step from the parent.

Androsterone arises from 5-alpha reduction and 3-alpha reduction of androgens derived from DHEA and is a major urinary end product of that pathway. It marks the disposal end of the same route.

Aromatase converts androstenedione, a direct DHEA metabolite, into oestrone. Chrysin is a flavone with aromatase-inhibiting activity in vitro, which is why it has long been co-formulated with DHEA, although its oral absorption is poor.

Part of a DHEA load is aromatised onward to oestrogens, which are then hydroxylated by CYP1A1 and CYP1B1. DIM shifts that hydroxylation balance, so it acts on the disposal side of the same pathway.

Steroid metabolites leave the body largely as glucuronide conjugates, and gut beta-glucuronidase can cleave those conjugates and return the steroid to circulation. Calcium D-glucarate yields glucaro-1,4-lactone, which inhibits that enzyme.

Pregnenolone branches either to progesterone through 3-beta-HSD or to DHEA through CYP17A1. The two arms draw on one precursor pool, so loading one branch changes what is available to the other.

Boron intake is associated with shifts in sex hormone binding globulin and in the free fraction of circulating steroids. That is an association with how much of a DHEA-derived androgen is unbound, not with how much is made.

The adrenal cortex holds one of the highest ascorbate concentrations of any tissue in the body, and ascorbate is consumed during steroidogenesis in the zona reticularis where DHEA is made. This is settled physiology of the gland rather than a supplementation result. It explains why the two appear together in adrenal-support formulas, and it is not a claim that adding ascorbate raises circulating DHEA.

Pantothenic acid is the backbone of coenzyme A, and acetyl-CoA is the starting point of the cholesterol synthesis that feeds every steroid including DHEA. Without adequate coenzyme A the whole steroidogenic supply chain slows. The relationship is upstream and nutritional, not a dose-response effect on circulating DHEA.

The first committed step of steroidogenesis happens on the inner mitochondrial membrane, where cholesterol side-chain cleavage depends on electron flow through the respiratory chain that ubiquinone carries. Ovarian and adrenal steroid output is therefore tied to mitochondrial competence. Products aimed at ovarian reserve routinely stack the two on this reasoning.

Myo-inositol and DHEA are combined in products aimed at ovarian response, where inositol acts on insulin signalling in the granulosa cell and DHEA supplies androgen substrate. A trial in the candidate set links the ovarian response to DHEA with androgen receptor expression, which is the receptor side of the same axis. The two arms have not been compared head to head in the candidate literature.

A 2026 meta-analysis of vitamin D supplementation tracked endocrine and metabolic markers, with DHEA sulfate among the androgen markers reported. Vitamin D receptors are present in steroidogenic tissue, which supplies the mechanism. The relationship is a measured marker association, not a demonstration that one raises the other.

An open-label flaxseed intervention reported reproductive endocrine profiles that include DHEA sulfate among the androgen markers followed. Lignans influence sex hormone binding globulin, which changes the free fraction of circulating androgens. This is an open-label marker readout, so it carries no control comparison.

Melatonin accumulates in follicular fluid and buffers oxidative stress in the same microenvironment where DHEA is converted to testosterone and then aromatised. Ovarian-support protocols stack them for that complementary reason: one supplies substrate, the other protects the compartment. The pairing rests on mechanism and use, not on a combination trial in this candidate set.

Zinc is a structural and catalytic component of enzymes across the androgen pathway and of the androgen receptor zinc fingers that read the signal once DHEA has been converted downstream. Adequate zinc status is therefore a precondition for the pathway operating normally. It is a permissive nutrient relationship, not an additive hormonal effect.

Every ATP-dependent step in the sulfation and desulfation cycle that stores DHEA as DHEA sulfate requires magnesium as the counter-ion of ATP. Sulfotransferase activity is nucleotide-dependent for that reason. This is background biochemistry rather than a supplementation interaction.

The sulfate group that converts DHEA to its circulating sulfated reservoir comes from PAPS, which is generated from inorganic sulfate produced by the molybdenum-dependent enzyme sulfite oxidase. Sulfur amino acid turnover therefore sits upstream of DHEA sulfate. The link is metabolic and does not imply that supplementing molybdenum changes DHEA sulfate concentrations.

N-acetylcysteine feeds the cysteine pool that is oxidised to inorganic sulfate and then activated to PAPS, the universal sulfate donor used by SULT2A1 to make DHEA sulfate. Sulfation capacity is substrate-limited when sulfur supply is low. The relationship is upstream substrate supply, not a hormonal effect.

Glycyrrhizin and its metabolite inhibit 11-beta-hydroxysteroid dehydrogenase type 2, which changes how the body handles cortisol and, with it, the mineralocorticoid balance that sits alongside adrenal androgen output. Combining a steroid precursor with an agent that alters steroid enzyme handling is a real pharmacological interaction. It is flagged as a caution for formulators, not as a benefit.

Ashwagandha is combined with DHEA in products aimed at the hypothalamic-pituitary-adrenal axis, where the botanical is studied for cortisol readouts and DHEA supplies steroid precursor. The two act at different points of the same axis. No combination trial exists in the candidate set, so the pairing is formulation logic.